Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia

被引:90
作者
Smesny, Stefan
Rosburg, Timm
Nenadic, Igor
Fenk, Klaus Peter
Kunstmann, Sebastian
Rzanny, Reinhardt
Volz, Hans-Peter
Sauer, Heinrich
机构
[1] Univ Jena, Dept Psychiat, D-07743 Jena, Germany
[2] Univ Jena, Dept Diagnost & Intervent Radiol, D-07740 Jena, Germany
[3] Univ Bonn, Dept Epileptol, D-53105 Bonn, Germany
[4] Dept Psychiat & Psychothearpy, D-97440 Werneck, Germany
关键词
schizophrenia; brain; (31)P-MRS; 2D-CSI phospholipids; white matter; energy metabolism;
D O I
10.1016/j.neuroimage.2006.12.023
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
(31)Phosphorus magnetic resonance spectroscopy ((31)P-MRS) allows in vivo investigation of cerebral phospholipid and energy metabolism. Using 2D chemical shift imaging, this method can be applied to study multiple brain areas and to assess concentrations of both phospholipids and high-energy phosphates. The purpose of our study was to assess multiregional metabolic profiles in schizophrenia using a 2D-resolved MRS technique, and to assess the intercorrelation of findings. We applied (31)P-MRS chemical shift imaging in 31 schizophrenia patients (12 antipsychotic-naive first-episode and 19 antipsychotic-free multi-episode patients) and 31 healthy age- and sex-matched controls. Spatially resolved maps were compared for the main metabolites of the (31)P spectrum. Metabolites of phospholipid (PME and PDE) and energy (PCr and Pi) metabolism were significantly reduced in bilateral prefrontal and medial temporal (including hippocampal) brain regions, caudate nucleus, thalamus and anterior cerebellum as compared to controls. Moreover, factor analysis of these changes showed a characteristic spatial pattern of changes, which demonstrates significant associations between alterations of phospholipid and energy metabolism, and between metabolic alterations and severity of symptoms (BPRS total score, but not SANS or SAPS scores). This suggests a pattern of intercorrelated changes of these metabolic markers. Results support the notion of disturbed phospholipid turnover in schizophrenia, probably unrelated to prior pharmacological treatment, and associated with increased energy demand. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:729 / 737
页数:9
相关论文
共 44 条
[1]   Phosphorus-31 magnetic resonance spectroscopy studies of pig spinal cord injury - Myelin changes, intracellular pH, and bioenergetics [J].
Akino, M ;
ODonnell, M ;
Robitaille, PML ;
Stokes, BT .
INVESTIGATIVE RADIOLOGY, 1997, 32 (07) :382-388
[2]  
Andreasen N, 1984, SCALE ASSESSMENT POS
[3]  
Andreasen N.C., 1983, SCALE ASSESSMENT POS
[4]   Implications of lipid biology for the pathogenesis of schizophrenia [J].
Berger, GE ;
Wood, SJ ;
Pantelis, C ;
Velakoulis, D ;
Wellard, RM ;
McGorry, PD .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2002, 36 (03) :355-366
[5]   Proton magnetic resonance spectroscopy in schizophrenia [J].
Bertolino, A ;
Weinberger, DR .
EUROPEAN JOURNAL OF RADIOLOGY, 1999, 30 (02) :132-141
[6]   Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia [J].
Bertolino, A ;
Esposito, G ;
Callicott, JH ;
Mattay, VS ;
Van Horn, JD ;
Frank, JA ;
Berman, KF ;
Weinberger, DR .
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (01) :26-33
[7]   White matter changes in schizophrenia - Evidence for myelin-related dysfunction [J].
Davis, KL ;
Stewart, DG ;
Friedman, JI ;
Buchsbaum, M ;
Harvey, PD ;
Hof, PR ;
Buxbaum, J ;
Haroutunian, V .
ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (05) :443-456
[8]   CORRELATION BETWEEN LEFT FRONTAL PHOSPHOLIPIDS AND WISCONSIN CARD SORT TEST-PERFORMANCE IN SCHIZOPHRENIA [J].
DEICKEN, RF ;
MERRIN, EL ;
FLOYD, TC ;
WEINER, MW .
SCHIZOPHRENIA RESEARCH, 1995, 14 (02) :177-181
[9]   Magnetic resonance spectroscopy [J].
Duncan, JS .
EPILEPSIA, 1996, 37 (07) :598-605
[10]   Phosphorus magnetic resonance spectroscopy in schizophrenia: Correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms [J].
Fukuzako, H ;
Fukuzako, T ;
Takeuchi, K ;
Ohbo, Y ;
Ueyama, K ;
Takigawa, M ;
Fujimoto, T .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1996, 20 (04) :629-640